Testosterone, Blood Flow, or Sensation? Which is Key to Unlocking Women's Desire and Sexual Pleasure?; Ask Experts What Works.

CHARLESTON, S.C. -- New studies and journal articles have raised serious questions about what really works to improve sex for women. Testosterone and blood flow appear to be taking a back seat to sensation.

The July 6, 2005, article in the Journal of the American Medical Association reports the finding that, "No single androgen (sex hormone) level was found to be predictive of low sexual function in women."(1)

This follows rapidly on a May 2005 study published in the American Journal of Obstetrics & Gynecology by researchers at Yale School of Medicine and the Albert Einstein College of Medicine. The study reported that, "Decreased tactile sensation was found at the clitoris for women with total sexual dysfunction, desire disorder and arousal disorder."(2)

"In addition to reports of low sex drive, women's health professionals often hear that some women 'feel dead down there,'" said gynecologist Elizabeth Baron-Kuhn. "Women are clearly more complex than men, and these new findings help to illuminate the underlying reasons why major drug companies have yet to succeed in developing an FDA approved prescription drug for women's sexual problems."

"It's time to recognize the required role that sensation has in female sexual response and explore non-hormonal options that can lift libido and make sex better for women," added Dr. Baron-Kuhn.

The following medical and sexual health experts are available for comment as non-paid members of a newly formed Sexual Wellness Panel:

--  Elizabeth Baron-Kuhn, MD, FACOG - A Board Certified
        Gynecologist at Riverside Gynecology and Women's Health in
        Waupaca, Wisconsin. With expertise in menopause and female
        sexual dysfunction, Dr. Baron-Kuhn initiated and delivered a
        two-year public health lecture series on topics centered
        around menopause and women's health including: "Understanding
        Menopause: What's Happening to Me?"

    --  Andre Theodore Guay, MD - A clinical assistant professor of
        medicine at Harvard Medical School and Director of the Center
        For Sexual Dysfunction at Lahey Clinic Northshore in Peabody
        and a senior staff physician in the Department of
        Endocrinology at the Lahey Clinic Medical Center, Burlington,
        MA.

    --  Harold Schulman, MD - Coauthor of Tipping The Scales, former
        professor at State University of New York at Stony Brook and
        former chairman of obstetrics/gynecology at Albert Einstein
        College of Medicine. Dr. Schulman is today a consultant and
        teacher in female ultrasound. He is working on a new book in
        the field of women's sexual power in societal affairs.

    --  Rosemarie Schulman, RN, BA, CH - Coauthor of Tipping the
        Scales and a radio and TV host. Established several health
        care centers incorporating alternative medicine in weight
        management. Currently heads the dietary and behavior
        management at the New York Medical College Bariatric Surgery
        division. In her work, Schulman addresses the association
        between weight-loss and sexual dysfunction.

    --  Susan Kellogg-Spadt, PhD, CRNP - Co-founder of the Pelvic &
        Sexual Health Institute at Graduate Hospital in Philadelphia
        where she has been the Director of Sexual Medicine for seven
        years. Dr. Kellogg-Spadt is also an assistant professor of
        OB/GYN at Robert Wood Johnson Medical School of the University
        of Medicine & Dentistry of New Jersey. In addition, Dr.
        Kellogg-Spadt has authored two books and more than 80 articles
        on women's sexual health.

The panel members will speak objectively about multidisciplinary approaches to improve sexual experiences for women, as part of a public education campaign. The campaign is supported by QualiLife Pharmaceuticals, developers of Zestra(TM) for Women. Zestra(TM) has been acknowledged in leading peer reviewed medical journals.

--  Obstetrical and Gynecological Survey - Continuing Medical
        Education (CME) Review
        In March 2005, Obstetrical and Gynecological Survey published
        a Continuing Medical Education (CME) Review Article that
        acknowledges the benefits of Zestra(TM) for both arousal and
        orgasmic difficulties. The objective of the CME Review Article
        titled "Female Sexual Dysfunction: Principles of Therapy" is
        to provide the most current clinical information available to
        Obstetricians and Gynecologists on the topic of female sexual
        dysfunction and the principles of diagnosis and therapy.

        The CME Review Article cites a clinical trial conducted by
        QualiLife Pharmaceuticals titled "Randomized
        Placebo-Controlled Double Blind, Crossover Design Trial of the
        Efficacy and Safety of Zestra for Women in Women With, and
        Without Female Sexual Arousal Disorder (FSAD)." The study of
        20 women showed improvement in level of desire, arousal,
        sensation, pleasure and ability to have orgasms in both normal
        and FSAD patients using Zestra(TM), as compared with placebo.
        To view the article abstract visit Obstetrical and
        Gynecological Survey's Web site at www.obgynsurvey.com.

    --  Association of Reproductive Health Professionals (ARHP)
        Clinical Proceedings(R)
        In May 2005, ARHP published Clinical Proceedings that is
        designated for Continuing Medical Education (CME).
        Clinical Proceedings also cites the clinical trial
        referenced above and recognizes Zestra(TM) as a treatment
        option for females with sexual arousal difficulties.
        Clinical Proceedings is part of a Nurture Your Nature
        initiative, a joint program of ARHP and the National
        Women's Health Resource Center to raise awareness about
        sexuality as a natural and valued aspect of American
        women's lives, with a focus on menopausal women. For
        full-text: http://www.healthywomen.org/sexuality/CPNYN.pdf.

About Non-Prescription Zestra(TM) Feminine Arousal Fluid (U.S. Patent 6,737,084)

Zestra(TM) is a patented blend of pure botanical oils and other natural ingredients scientifically formulated to heighten sexual sensation, arousal and pleasure for 30 to 45 minutes when topically applied. The ingredients in Zestra(TM) are not found in any other women's sexual product. No other product is proven to be more effective for increasing female sexual sensation, arousal, pleasure, satisfaction and libido. Ingredients: PA-Free Borage Seed Oil, Evening Primrose Oil, Angelica Extract, Coleus Extract, Vitamin C, Vitamin E and natural fragrances. More information is available at www.zestraforwomen.com.

Zestra(TM) is available nationwide in Walgreen's, CVS and Duane Reade pharmacies.

About QualiLife Pharmaceuticals, Inc.

QualiLife Pharmaceuticals, Inc. is a science-driven company focused on developing clinically proven consumer products for Women's Health. Since 1996, the Company has leveraged its expertise in pharmacology, pharmaceutical technology and women's sexual health to "design and develop" selected plant-derived principles as patented consumer products with significant commercial potential.

(1)Journal of the American Medical Association, July 6, 2005; vol 294: pp 91-96. Susan Davis, MD, PhD, Women's Health Program, department of medicine, Monash Medical School, Alfred Hospital, Victoria, Australia.

(2)American Journal of Obstetrics & Gynecology, Vol. 192, No. 5 (May 2005), Kathleen Connell, MD; Marsha K. Guess, MD; Julie La Combe, MD; Andrea Wang, MD; Kenneth Powers, MD; George Lazarou, MD; Magdy Mikhail, MD; Yale School of Medicine and the Albert Einstein College of Medicine. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&d opt=Abstract&list_uids=15902183&query_hl=2 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)